Rafferty Asset Management, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Rafferty Asset Management, LLC

$26.8 Billion
Q2 2024

A detailed history of Rafferty Asset Management, LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 183,293 shares of CERE stock, worth $0. This represents 0.03% of its overall portfolio holdings.

Number of Shares

183,293

Previous 222,314 17.55%

Holding current value

Previous $9.4 Million 20.25%

% of portfolio

0.03%

Previous 0.04%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$38.96 - $42.75 $1.52 Million - $1.67 Million	-39,021 Reduced 17.55%	183,293 $7.49 Million
Q1 2024 May 13, 2024	BUY	$40.88 - $43.27 $3.3 Million - $3.5 Million	80,837 Added 57.14%	222,314 $9.4 Million
Q4 2023 Feb 13, 2024	SELL	$20.27 - $42.44 $1.17 Million - $2.44 Million	-57,516 Reduced 28.9%	141,477 $6 Million
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $451,554 - $711,210	22,288 Added 12.61%	198,993 $4.34 Million
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $800,172 - $1.18 Million	-33,480 Reduced 15.93%	176,705 $5.62 Million
Q1 2023 May 11, 2023	SELL	$22.82 - $35.32 $649,685 - $1.01 Million	-28,470 Reduced 11.93%	210,185 $5.13 Million
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $2.22 Million - $2.79 Million	87,413 Added 57.8%	238,655 $7.53 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $1.97 Million - $3.2 Million	77,264 Added 104.44%	151,242 $4.27 Million
Q2 2022 Aug 12, 2022	SELL	$20.62 - $37.15 $804,613 - $1.45 Million	-39,021 Reduced 34.53%	73,978 $1.96 Million
Q1 2022 May 13, 2022	SELL	$23.5 - $35.38 $521,653 - $785,365	-22,198 Reduced 16.42%	112,999 $3.96 Million
Q4 2021 Feb 10, 2022	BUY	$29.21 - $44.64 $1.56 Million - $2.38 Million	53,303 Added 65.09%	135,197 $4.38 Million
Q3 2021 Nov 10, 2021	BUY	$21.26 - $38.85 $851,654 - $1.56 Million	40,059 Added 95.75%	81,894 $2.42 Million
Q2 2021 Aug 10, 2021	SELL	$12.56 - $29.69 $248,060 - $586,377	-19,750 Reduced 32.07%	41,835 $1.07 Million
Q1 2021 May 10, 2021	BUY	$12.37 - $17.74 $761,806 - $1.09 Million	61,585 New	61,585 $846,000

Others Institutions Holding CERE

# of Institutions

242

Shares Held

154M

Call Options Held

2.19M

Put Options Held

3.87M

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Cerevel Therapeutics Holdings, Inc. Transaction History